Search
Bismuth subsalicylate
go.drugbank.com/drugs/DB01294ApprovedVet approvedEach molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. … [A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort.
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme
Factor IX Complex (Human)
go.drugbank.com/drugs/DB11330ApprovedInvestigationalCoagulation factors are purified from pooled human plasma and subsequently sterilized and treated. … As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients
Products: BERIPLEX P/N 250 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, BERIPLEX P/N 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETPhentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointe...
Synonyms: 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazolineAminophenazone
go.drugbank.com/drugs/DB01424ApprovedWithdrawnAminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to ...
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine's mechanism of action is not well understood, but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and stabilizing the inactivated state of
Dipyridamole
go.drugbank.com/drugs/DB00975ApprovedInvestigational(From AMA Drug Evaluations Annual, 1994, p752) … A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin.
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalBy blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration
Tubocurarine
go.drugbank.com/drugs/DB01199ApprovedWithdrawn[A216008] Curare is one of the names used to describe plant-derived poisons used by indigenous South Americans to coat the tips of hunting arrows and darts, which were typically derived from plants of … [A216038] Tubocurarine's clinical use was limited by its relatively long duration of action (30-60 minutes)[A216038] and a number of significant side effects.
Sutilain
go.drugbank.com/drugs/DB09379ApprovedWithdrawnSutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder. … [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]